Related Experiment Video

Updated: Aug 21, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Peginterferon-alpha(2b) and ribavirin

Joseph Ahn1, Steven Flamm

  • 1Department of Medicine, Northwestern University Medical School, Northwestern Memorial Hospital, Chicago, IL 60611, USA.

Expert Review of Anti-Infective Therapy
|October 16, 2004
PubMed

Insights

Pegylated interferon-alpha(2b) combined with ribavirin offers improved efficacy for treating chronic hepatitis C virus infection compared to standard interferon. This combination therapy demonstrates safety and ease of use for patients.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease globally, affecting 300 million people.
  • HCV is the primary indication for liver transplantation in the USA, with projected growth in cases.
  • Previous treatments like interferon-alpha(2b) monotherapy and combination therapy showed limited success.

Purpose of the Study:

  • To review data on pegylated interferon-alpha(2b) (Peg-intron) with ribavirin therapy for chronic hepatitis C virus infection.
  • To present pharmacokinetics, pharmacodynamics, and clinical trial data for this combination therapy.

Main Methods:

  • Review of clinical trial data on pegylated interferon-alpha(2b) and ribavirin combination therapy.
  • Analysis of pharmacokinetic and pharmacodynamic properties of the combined treatment.

Main Results:

  • Pegylated interferon combination therapy demonstrated improved efficacy over standard interferon combination therapy.
  • The combination therapy did not show an increase in adverse effects compared to standard treatments.
  • The efficacy and ease of use of Pegintron and ribavirin support their application.

Conclusions:

  • Pegylated interferon-alpha(2b) with ribavirin is an effective treatment for chronic hepatitis C virus infection.
  • This combination therapy represents a significant advancement in HCV treatment.
  • The safety and efficacy profile supports its widespread use in managing chronic hepatitis C.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...